in conclusion , this study demonstrates that reactivity to interleukin 2 distinguishes inflammatory bowel disease from control intestinal mononuclear cells , and , under appropriate experimental conditions , it can be used to uncover abnormalities of intestinal immunity .
C0021390
inflammatory bowel disease
C0021853
intestinal